Compounds > zm 241385
Page last updated: 2024-09-05

zm 241385 and Cardiovascular Stroke

zm 241385 has been researched along with Cardiovascular Stroke in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (75.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lochner, A; Moolman, JA; Salie, R1
Ballard-Croft, C; Keith, BJ; Kristo, G; Lasley, RD; Mentzer, RM; Reid, EA; Yoshimura, Y1
Amerson, BS; Guyton, RA; Halkos, ME; Headrick, JP; Kerendi, F; Kin, H; Lofye, MT; Vinten-Johansen, J; Zatta, AJ; Zhao, ZQ1
Auchampach, JA; Ge, ZD; Gross, GJ; Jacobson, MA; Kreckler, LM; Peart, JN; Wan, TC1

Other Studies

4 other study(ies) available for zm 241385 and Cardiovascular Stroke

ArticleYear
The mechanism of beta-adrenergic preconditioning: roles for adenosine and ROS during triggering and mediation.
    Basic research in cardiology, 2012, Volume: 107, Issue:5

    Topics: Adenosine; Animals; Ethanolamines; Extracellular Signal-Regulated MAP Kinases; Formoterol Fumarate; Ischemic Preconditioning, Myocardial; Isoproterenol; Myocardial Infarction; Phosphatidylinositol 3-Kinases; Potassium Channels; Protein Kinase C; Proto-Oncogene Proteins c-akt; Rats; Reactive Oxygen Species; Receptors, Adrenergic, beta; Receptors, Purinergic P1; Triazines; Triazoles

2012
In vivo adenosine receptor preconditioning reduces myocardial infarct size via subcellular ERK signaling.
    American journal of physiology. Heart and circulatory physiology, 2005, Volume: 288, Issue:5

    Topics: Animals; Butadienes; Enzyme Inhibitors; Imidazoles; Ischemic Preconditioning, Myocardial; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myocardial Infarction; Nitriles; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P1; Reperfusion Injury; Subcellular Fractions; Triazines; Triazoles; Xanthines

2005
Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine.
    Cardiovascular research, 2005, Jul-01, Volume: 67, Issue:1

    Topics: Adenosine; Animals; Male; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Perfusion; Purinergic P1 Receptor Antagonists; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P1; Theophylline; Triazines; Triazoles; Xanthines

2005
Cl-IB-MECA [2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide] reduces ischemia/reperfusion injury in mice by activating the A3 adenosine receptor.
    The Journal of pharmacology and experimental therapeutics, 2006, Volume: 319, Issue:3

    Topics: Adenosine; Adenosine A3 Receptor Agonists; Animals; Blood Pressure; Cardiotonic Agents; Cell Degranulation; Cells, Cultured; Cyclic AMP; Dose-Response Relationship, Drug; Histamine; In Vitro Techniques; Male; Mice; Mice, Knockout; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; p-Methoxy-N-methylphenethylamine; Pyridines; Radioligand Assay; Receptor, Adenosine A3; Triazines; Triazoles

2006